CA2407958A1 - Crystalline polymeric compositions for ophthalmic devices - Google Patents
Crystalline polymeric compositions for ophthalmic devices Download PDFInfo
- Publication number
- CA2407958A1 CA2407958A1 CA002407958A CA2407958A CA2407958A1 CA 2407958 A1 CA2407958 A1 CA 2407958A1 CA 002407958 A CA002407958 A CA 002407958A CA 2407958 A CA2407958 A CA 2407958A CA 2407958 A1 CA2407958 A1 CA 2407958A1
- Authority
- CA
- Canada
- Prior art keywords
- ophthalmic device
- polymeric material
- lens
- crystalline
- incision
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/16—Intraocular lenses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/145—Corneal inlays, onlays, or lenses for refractive correction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/14—Eye parts, e.g. lenses, corneal implants; Implanting instruments specially adapted therefor; Artificial eyes
- A61F2/16—Intraocular lenses
- A61F2002/1681—Intraocular lenses having supporting structure for lens, e.g. haptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/16—Materials or treatment for tissue regeneration for reconstruction of eye parts, e.g. intraocular lens, cornea
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S623/00—Prosthesis, i.e. artificial body members, parts thereof, or aids and accessories therefor
- Y10S623/902—Method of implanting
- Y10S623/905—Eye
- Y10S623/907—Method of manipulating parts of intraocular lens structure for implantation
Abstract
Ophthalmic devices suitable for implantation into the eye through small incisions are disclosed. These devices are made from a composition comprising crystalline or semi-crystalline polymeric materials which have a glass transition temperature (Tg) of from about -100 ~C to about 20 ~C, a melting point temperature (Tm) of from about 0 ~C to about 37 ~C, and wherein Tg for the material is lower than Tm for the composition. Disclosed devices include intraocular lenses, corneal inlays, ocular drug delivery devices and implants for reducing intraocular pressure in glaucoma patients; intraocular lenses are preferred.
Description
CRYSTALLINE POLYMERIC COMPOSITIONS FOR OPHTHALMIC DEVICES
STEPHEN Q. ZHOU
CHRISTOPHER D. WILCOX
CHRISTINE LIAU
S IGOR VALYUNIN
BACKGROUND OF THE INVENTION
This application is based on and claims priority from US Provisional Application No. 60/206,197, filed May 22, 2000.
Eye surgeries involving ophthalmic devices usually require an incision for introducing the ophthalmic device to the target location for their intended use.
Often, it is desirable to make the incision size as small as possible for fast recovery 1 S and for minimizing potential post-operational complications and side effects. In order to understand this general small incision concept, the following examples axe given for the purpose of illustration, but not to limit the scope of the present invention.
Intraocular lenses (IOLs) have been used as the replacement for the crystalline lens after cataract surgery and as a phakic lens which functions together with the intact crystalline lens for correcting refractive errors. To surgically implant an intraocular lens (IOL) or phalcic lens into the eye, an incision is made on the cornea. It is desirable to keep the incision size as small as possible.
Implanting a traditional polymethyl methacrylate (PMMA) IOL or a PMMA phakic lens requires an incision size of about 6 mm simply because the hard PMMA lens has an optical diameter of approximately 6 mm. In order to reduce the incision size, soft materials, such as silicone or soft acrylic material have been used for lenses. A soft lens can be folded in half and then implanted into an eye with an incision size of about 3 mm.
The reduction in incision size has been proven in clinical studies to reduce surgically induced astigmatism, hasten wound healing, and reduce risk of infection and/or inflammation.
Corneal inlay is an ophthalmic device surgically implanted within the cornea.
A corneal inlay is designed as a lens, about 2 to 3 mm in diameter, which provides a central nearsighted vision zone for presbyopic patients. The natural cornea surrounding the inlay provides the patient with the farsighted vision. The human cornea has a thickness of approximately 0.5 mm. To implant a thin inlay lens into the cornea, the first step is to make an incision on the corneal surface without cutting through the whole corneal layer. The second step is to make a pocket within the corneal layer with the initial incision as the pocket opening. The incision should have a sufficient width so that the artificial inlay lens can be introduced into the pocket. For example, if a hard corneal inlay lens, such as a PMMA lens, is used, the minimum incision size needs to be about the same as the diameter of the PMMA
lens. As with an IOL, a deformable inlay lens allows a reduced incision size and, therefore, reduced surgical trauma.
Cytomegalovirus (CMV) infection of the retina, or CMV retinitis, usually leads to blindness if untreated. CMV retinitis progresses very rapidly, particularly in HIV patients, often within weeks. One of the treatments is to introduce an anti-CMV drug inside the eye by a slow release drug delivery device through the cornea or the sclera. To implant the drug delivery device into the eye, a small incision or hole is cut through the cornea. Then the drug delivery device is pushed through the incision or the hole. For this application, it will be ideal if the drug delivery device is a hard solid rod for easy insertion. When the drug delivery device is inside the eye, it becomes soft. In addition, if the drug delivery device can be stretched into a smaller profile, it will be implanted into a reduced incision size or hole diameter.
Therefore, surgical trauma is minimized.
From the examples given above, there is a need for ophthalmic devices which can be implanted into an opening which has a size smaller than the dimension of the ophthalmic device in its intended use conditions. Furthermore, the ideal ophthalmic device is a hard solid at the time of implantation so that it can be relatively easily implanted into the soft tissue opening. In addition, when warmed by the body temperature, the "ideal" hard solid ophthalmic device can become soft and pliable for optimal tissue compatibility.
The crystalline state of polymers is defined as one that diffracts x-rays and exhibits the first order transition known as melting (L.H. Sperling, Ihtroductiofz to Physical Polymer Sciefzce, John Wiley & Sons, New York, 1992). As in small molecules, crystallinity occurs when parts of a molecule arrange themselves in a regular order or arrangement. Unlike a small molecule, polymers that crystallize in the bulk state are never totally crystalline, a consequence of their Long-chain nature and the chain entanglements. Even in homopolymers, there will be crystalline and amorphous regions. Polymers that have crystalline regions may be referred to as crystalline or semi-crystalline polymers. The development of crystallinity depends on the stnzcture regularity in the polymer. An increase in non-regularity of the polymer structure decreases crystallinity of the polymer and results in a lower melting temperature. The increase in non-regularity may eventually prevent crystalline regions from forming.
The present invention utilizes crystalline polymers which provide a novel mechanism for deforming ophthalmic devices made from those polymers into a smaller profile than their initial size, at least in one dimension, so that they can be implanted into the eye through a relatively small incision. When the ophthalmic device is placed in the targeted location, it will return to its intended shape and dimension or adapt to a new configuration shaped by the tissue surrounding the ophthalmic device.
The present invention includes crystalline polymers that may be useful in the production of deformable lenses such as IOLs for cataract surgery, corneal inlays, and phakic refractive lenses for correcting ametropia, such as myopia, hyperopia, astigmatism, and presbyopia. The present invention also includes the use of crystalline polymers in ophthalmic devices which are not lens related. Such non-lens related devices may include, but are not limited to, ocular drug delivery devices, and implants for reducing intraocular pressure in glaucoma patients.
Stoy in his US Patent 4,731,079, issued March 15, 1988, discloses a method of introducing and implanting an artificial intraocular lens to replace a surgically removed human crystalline lens through a small incision. The artificial lens material has a softening temperature in the range of about 0°C to about 42°C. The method comprises the following steps: First, heat the artificial lens to a temperature higher than its softening temperature; second, deform the artificial lens into a smaller profile at least in one dimension so that it can be implanted through a small incision into the eye; third, cool down the deformed artificial lens to a temperature which is at least 5°C less than the softening temperature, so that the artificial lens will be frozen in the deformed configuration; fourth, implant the deformed lens into the eye through a small incision. After being warmed up by the eye temperature, the deformed lens will return to its pre-deforned shape and dimension. Stoy further teaches that preferred materials include terpolyrners which contain both hydrophobic and hydrophilic monomers as well as a minor amount of monomers with at least two polymerizable double bonds. These terpolymers can be hydrated due to the presence of a desirable amount of hydrophilic monomers. The plasticizer, water in the case of the terpolymer, can lower the softening temperature of the lens material. Stoy indicates that the softelung temperature may correspond to the glass transition temperature (Tg). However, Stoy is silent on whether the softening temperature can be a melting temperature (Tm). Those who are skilled in the art understand that only a crystalline polymer can have a Tm and that a crystalline polymer is typically not transparent due to the presence of crystalline structure. According to Stoy, one of the requirements for his invention is that the material must be highly transparent to visible light. Stoy further teaches that preferred polymers for use in his invention axe amorphous, without a substantial amount of crystalline polymer phase being present.
MemoryLensTM° a commercially available implantable lens, is made from the terpolymer of methyl methacrylate (MMA), hydroxyethyl methacrylate (HEMA),~
and a minor amount of crosslinlcer. According to Dr. William J. Fishkind, MemoryLens has a composition of MMA and HEMA such that the fully hydrated lens material contains approximately 20% water and has a refractive index of 1.47.
At temperatures below 25°C, the copolymer is rigid and hard, while at temperatures above 25°C, the copolymer begins to soften and becomes elastic. This thermoplastic characteristic of the copolymer is a function of its glass transition temperature (Tg).
The MemoryLens is rolled when it is soft by increasing the temperature above its Tg, and then hardened in a fixed and rolled configuration by cooling to temperatures below its Tg. This hardened rolled lens is implanted into the eye through a small incision. Once placed inside the eye, the lens starts to become soft and relaxes to resume its pre-rolled shape. The complete shape recovery may talce hours to one day to finish. Dr. Fishl~ind has indicated that on the first postoperative day, the folding lines will have completely resolved. (William J. Fishkind, MD, Chapter "ORC lVIemoryLensTM - A thermoplastic IOL" in the book titled Foldable Iratraocular Lenses by Robert G. Martin, James P. Gills, and Donald R.
Sanders, SLACK Incorporated, 1993).
CopendW g US Patent Application Serial No. 091361,729, filed July 27, 1999, describes a punctal plug formed from a material which can be deformed to a convenient shape for insertion into the punctum, frozen into that shape, and which regains its original shape after insertion and warming. The optical characteristics of a punctal plug are not relevant to its operability. Further, no optical devices which are inserted into the eye through a hole or incision, such as intraocular lenses, are disclosed.
SUMMARY OF THE INVENTION
The present invention relates to an ophthalmic device suitable for implantation through an incision in the human eye (such as an ocular drug delivery device, an implant for reducing intraocular pressure, a corneal inlay, or , most preferably, an intraocular lens), made from a composition containing a cxystalline or semi-crystalline polymeric material having the following properties:
(a) a glass transition temperature (Tg) in the range of from about -100°C
to about 20°C;
(b) a melting temperature (Tm) in the range of from about 0°C to about 37°C; and (c) wherein said glass transition temperature of the polymeric material is lower than said melting temperature for the composition.
The present invention also relates to a method for implanting into the eye, through an incision, an ophthalmic device made from a composition containing a crystalline or semi-crystalline polymeric material with a Tg in the range of from _g_ about -100°C to about 20°C, and a Tm in the range of from about 0°C to about 37°C, comprising the steps of (a) warming up said ophthalmic device to or above its Tm, then deforming said ophthalmic device into a deformed shape which can be implanted through an incision where the size of said incision is smaller than said ophthalmic device in its intended use condition;
(b) cooling said deformed ophthalmic device to a temperature below the Tm such that said ophthalmic device remains in said deformed shape;
(c) implanting said deformed ophthalmic device at a temperature below the Tm through said incision in the eye; and (d) warming up said ophthalmic device to and above its Tm by the body temperature in the eye, whereupon said ophthalmic device changes into a shape suitable for its intended use.
BRIEF DESCRIPTION OF THE DRAWINGS
Figures 1-10 are top views showing examples of lens designs which may be used in the present invention.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is related to ophthalmic devices and their compositions derived from crystalline polymeric materials having a crystalline melting temperature (Tm) in the range of about 0°C to about 37°C, preferably in the range of about 15°C to about 30°C. In addition to the Tm, these crystalline polymeric materials also have a Tg (glass transition temperature) which is lower than the Tm for the given composition and is in the range from about -100°C to about 20°C, preferably in the range of about -100°C to about -17°C. Unlike the hydrogel materials taught' in the Stoy, et al. patent, discussed above, the Tm and Tg properties of the materials used in the present invention are not dependent on being in osmotic equilibrium in the body (i.e., Tm and Tg do not change in the presence of eye liquids). Although there are many different polymer structures which can form the desired crystalline regions, the preferred embodiments of the present invention include side chain crystalline-inducing polymers. The more preferred embodiments are the acrylic family polymers With long side chain alkyls (more than twelve carbons) as the crystalline-inducing groups.
It is well known to whose who are skilled in the art that as the length of the side chain of an acrylic ester monomer increases, the Tg of the homopolymer decreases. For example, CHz = CH(R) - COO R' Where R = H or CH3; and R' = alkyl groups, such as CH3-(CHa)"- , n = 0 to 19.
When R = CH3, and R' is the alkyl group where n increases from 0 to 17, then Tg of the homopolymer of the respective monomer decreases. The trend is illustrated in Table 1. Additionally, as n increases from 11 (lauryl methacrylate) to 17 (stearyl.
methacrylate), side chain crystallinity starts to form. For example, polystearyl methacrylate (n = 17 in R') has a side chain crystalline formation with a Tm of about 36°C.
Table 1. Physical Properties of Methacrylate Homopolymers in Literature~l~
n Polymer Name Tg (C) Tm (C) 0 Poly(methyl methacrylate)105 N/A
1 Poly(ethyl methacrylate) 65 N/A
3 Poly(butyl methacrylate) 20 N/A
11 Poly(lauryl methacrylate)-65 N/A
17 Poly(stearyl methacxylate)-100 36 Note: (1) Herman F. Mark, et al, Encyclopedia of Polymer Science and Engineering, Volume l, Pages 234 - 299, John Wiley & Sons, Inc. 1985.
The melting temperature, or Tm, is a characteristic of crystalline or semi-crystalline polymers. Melting may be observed visually in some materials, as the temperature increases when a material changes from white or opaque to hazy or transparent. Before the advent of sophisticated instrumental methods, melting temperatures were determined by viewing the melting polymer under a microscope between crossed polarizers. Dilatometry, where volume changes are measured, is another method for finding Tm. The use of a differential scanning calorimeter (DSC) is a popular method for examining the melting transition and is used for the determination of the Tm in the present invention.
Polystearyl methacrylate (SMA) is a white solid polymer at room temperature in its crystalline form. However, polystearyl methacrylate is found to be transparent when it is warmed up to a temperature higher than its melting temperature and its side chain crystalline structure melts. Because polystearyl methacrylate has a Tg of about -100°C, it is an elastomer after it melts. These dual thermodynamic properties, one corresponding to Tg and another corresponding to Tm, are required for the crystalline polymers in the present invention.
However, the homopolymer of stearyl methacrylate is tacky after it melts. This tackiness can be reduced by copolymerization with other monomers, such as methyl methacrylate (MMA). This tackiness can be further reduced by adding and increasing the amount of crosslinkers. Crosslinkers (for example, EGDMA, ethylene glycol dimethacrylate) can also improve the elasticity of the crystalline polymer, and therefore increase its capability for recovery from a deformed state. Table 2 is a summary of examples for the present invention.
Table 2. Examples . for Compositions and Their Properties of the Present Invention No.SMA % MMA % (by EGDMA% (by RefractiveTm (C) Tg wei ht wei ht wei ht ~l~ Index 35C (C) 1 100% 0% 0% 1.470 34 -100 Z
STEPHEN Q. ZHOU
CHRISTOPHER D. WILCOX
CHRISTINE LIAU
S IGOR VALYUNIN
BACKGROUND OF THE INVENTION
This application is based on and claims priority from US Provisional Application No. 60/206,197, filed May 22, 2000.
Eye surgeries involving ophthalmic devices usually require an incision for introducing the ophthalmic device to the target location for their intended use.
Often, it is desirable to make the incision size as small as possible for fast recovery 1 S and for minimizing potential post-operational complications and side effects. In order to understand this general small incision concept, the following examples axe given for the purpose of illustration, but not to limit the scope of the present invention.
Intraocular lenses (IOLs) have been used as the replacement for the crystalline lens after cataract surgery and as a phakic lens which functions together with the intact crystalline lens for correcting refractive errors. To surgically implant an intraocular lens (IOL) or phalcic lens into the eye, an incision is made on the cornea. It is desirable to keep the incision size as small as possible.
Implanting a traditional polymethyl methacrylate (PMMA) IOL or a PMMA phakic lens requires an incision size of about 6 mm simply because the hard PMMA lens has an optical diameter of approximately 6 mm. In order to reduce the incision size, soft materials, such as silicone or soft acrylic material have been used for lenses. A soft lens can be folded in half and then implanted into an eye with an incision size of about 3 mm.
The reduction in incision size has been proven in clinical studies to reduce surgically induced astigmatism, hasten wound healing, and reduce risk of infection and/or inflammation.
Corneal inlay is an ophthalmic device surgically implanted within the cornea.
A corneal inlay is designed as a lens, about 2 to 3 mm in diameter, which provides a central nearsighted vision zone for presbyopic patients. The natural cornea surrounding the inlay provides the patient with the farsighted vision. The human cornea has a thickness of approximately 0.5 mm. To implant a thin inlay lens into the cornea, the first step is to make an incision on the corneal surface without cutting through the whole corneal layer. The second step is to make a pocket within the corneal layer with the initial incision as the pocket opening. The incision should have a sufficient width so that the artificial inlay lens can be introduced into the pocket. For example, if a hard corneal inlay lens, such as a PMMA lens, is used, the minimum incision size needs to be about the same as the diameter of the PMMA
lens. As with an IOL, a deformable inlay lens allows a reduced incision size and, therefore, reduced surgical trauma.
Cytomegalovirus (CMV) infection of the retina, or CMV retinitis, usually leads to blindness if untreated. CMV retinitis progresses very rapidly, particularly in HIV patients, often within weeks. One of the treatments is to introduce an anti-CMV drug inside the eye by a slow release drug delivery device through the cornea or the sclera. To implant the drug delivery device into the eye, a small incision or hole is cut through the cornea. Then the drug delivery device is pushed through the incision or the hole. For this application, it will be ideal if the drug delivery device is a hard solid rod for easy insertion. When the drug delivery device is inside the eye, it becomes soft. In addition, if the drug delivery device can be stretched into a smaller profile, it will be implanted into a reduced incision size or hole diameter.
Therefore, surgical trauma is minimized.
From the examples given above, there is a need for ophthalmic devices which can be implanted into an opening which has a size smaller than the dimension of the ophthalmic device in its intended use conditions. Furthermore, the ideal ophthalmic device is a hard solid at the time of implantation so that it can be relatively easily implanted into the soft tissue opening. In addition, when warmed by the body temperature, the "ideal" hard solid ophthalmic device can become soft and pliable for optimal tissue compatibility.
The crystalline state of polymers is defined as one that diffracts x-rays and exhibits the first order transition known as melting (L.H. Sperling, Ihtroductiofz to Physical Polymer Sciefzce, John Wiley & Sons, New York, 1992). As in small molecules, crystallinity occurs when parts of a molecule arrange themselves in a regular order or arrangement. Unlike a small molecule, polymers that crystallize in the bulk state are never totally crystalline, a consequence of their Long-chain nature and the chain entanglements. Even in homopolymers, there will be crystalline and amorphous regions. Polymers that have crystalline regions may be referred to as crystalline or semi-crystalline polymers. The development of crystallinity depends on the stnzcture regularity in the polymer. An increase in non-regularity of the polymer structure decreases crystallinity of the polymer and results in a lower melting temperature. The increase in non-regularity may eventually prevent crystalline regions from forming.
The present invention utilizes crystalline polymers which provide a novel mechanism for deforming ophthalmic devices made from those polymers into a smaller profile than their initial size, at least in one dimension, so that they can be implanted into the eye through a relatively small incision. When the ophthalmic device is placed in the targeted location, it will return to its intended shape and dimension or adapt to a new configuration shaped by the tissue surrounding the ophthalmic device.
The present invention includes crystalline polymers that may be useful in the production of deformable lenses such as IOLs for cataract surgery, corneal inlays, and phakic refractive lenses for correcting ametropia, such as myopia, hyperopia, astigmatism, and presbyopia. The present invention also includes the use of crystalline polymers in ophthalmic devices which are not lens related. Such non-lens related devices may include, but are not limited to, ocular drug delivery devices, and implants for reducing intraocular pressure in glaucoma patients.
Stoy in his US Patent 4,731,079, issued March 15, 1988, discloses a method of introducing and implanting an artificial intraocular lens to replace a surgically removed human crystalline lens through a small incision. The artificial lens material has a softening temperature in the range of about 0°C to about 42°C. The method comprises the following steps: First, heat the artificial lens to a temperature higher than its softening temperature; second, deform the artificial lens into a smaller profile at least in one dimension so that it can be implanted through a small incision into the eye; third, cool down the deformed artificial lens to a temperature which is at least 5°C less than the softening temperature, so that the artificial lens will be frozen in the deformed configuration; fourth, implant the deformed lens into the eye through a small incision. After being warmed up by the eye temperature, the deformed lens will return to its pre-deforned shape and dimension. Stoy further teaches that preferred materials include terpolyrners which contain both hydrophobic and hydrophilic monomers as well as a minor amount of monomers with at least two polymerizable double bonds. These terpolymers can be hydrated due to the presence of a desirable amount of hydrophilic monomers. The plasticizer, water in the case of the terpolymer, can lower the softening temperature of the lens material. Stoy indicates that the softelung temperature may correspond to the glass transition temperature (Tg). However, Stoy is silent on whether the softening temperature can be a melting temperature (Tm). Those who are skilled in the art understand that only a crystalline polymer can have a Tm and that a crystalline polymer is typically not transparent due to the presence of crystalline structure. According to Stoy, one of the requirements for his invention is that the material must be highly transparent to visible light. Stoy further teaches that preferred polymers for use in his invention axe amorphous, without a substantial amount of crystalline polymer phase being present.
MemoryLensTM° a commercially available implantable lens, is made from the terpolymer of methyl methacrylate (MMA), hydroxyethyl methacrylate (HEMA),~
and a minor amount of crosslinlcer. According to Dr. William J. Fishkind, MemoryLens has a composition of MMA and HEMA such that the fully hydrated lens material contains approximately 20% water and has a refractive index of 1.47.
At temperatures below 25°C, the copolymer is rigid and hard, while at temperatures above 25°C, the copolymer begins to soften and becomes elastic. This thermoplastic characteristic of the copolymer is a function of its glass transition temperature (Tg).
The MemoryLens is rolled when it is soft by increasing the temperature above its Tg, and then hardened in a fixed and rolled configuration by cooling to temperatures below its Tg. This hardened rolled lens is implanted into the eye through a small incision. Once placed inside the eye, the lens starts to become soft and relaxes to resume its pre-rolled shape. The complete shape recovery may talce hours to one day to finish. Dr. Fishl~ind has indicated that on the first postoperative day, the folding lines will have completely resolved. (William J. Fishkind, MD, Chapter "ORC lVIemoryLensTM - A thermoplastic IOL" in the book titled Foldable Iratraocular Lenses by Robert G. Martin, James P. Gills, and Donald R.
Sanders, SLACK Incorporated, 1993).
CopendW g US Patent Application Serial No. 091361,729, filed July 27, 1999, describes a punctal plug formed from a material which can be deformed to a convenient shape for insertion into the punctum, frozen into that shape, and which regains its original shape after insertion and warming. The optical characteristics of a punctal plug are not relevant to its operability. Further, no optical devices which are inserted into the eye through a hole or incision, such as intraocular lenses, are disclosed.
SUMMARY OF THE INVENTION
The present invention relates to an ophthalmic device suitable for implantation through an incision in the human eye (such as an ocular drug delivery device, an implant for reducing intraocular pressure, a corneal inlay, or , most preferably, an intraocular lens), made from a composition containing a cxystalline or semi-crystalline polymeric material having the following properties:
(a) a glass transition temperature (Tg) in the range of from about -100°C
to about 20°C;
(b) a melting temperature (Tm) in the range of from about 0°C to about 37°C; and (c) wherein said glass transition temperature of the polymeric material is lower than said melting temperature for the composition.
The present invention also relates to a method for implanting into the eye, through an incision, an ophthalmic device made from a composition containing a crystalline or semi-crystalline polymeric material with a Tg in the range of from _g_ about -100°C to about 20°C, and a Tm in the range of from about 0°C to about 37°C, comprising the steps of (a) warming up said ophthalmic device to or above its Tm, then deforming said ophthalmic device into a deformed shape which can be implanted through an incision where the size of said incision is smaller than said ophthalmic device in its intended use condition;
(b) cooling said deformed ophthalmic device to a temperature below the Tm such that said ophthalmic device remains in said deformed shape;
(c) implanting said deformed ophthalmic device at a temperature below the Tm through said incision in the eye; and (d) warming up said ophthalmic device to and above its Tm by the body temperature in the eye, whereupon said ophthalmic device changes into a shape suitable for its intended use.
BRIEF DESCRIPTION OF THE DRAWINGS
Figures 1-10 are top views showing examples of lens designs which may be used in the present invention.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is related to ophthalmic devices and their compositions derived from crystalline polymeric materials having a crystalline melting temperature (Tm) in the range of about 0°C to about 37°C, preferably in the range of about 15°C to about 30°C. In addition to the Tm, these crystalline polymeric materials also have a Tg (glass transition temperature) which is lower than the Tm for the given composition and is in the range from about -100°C to about 20°C, preferably in the range of about -100°C to about -17°C. Unlike the hydrogel materials taught' in the Stoy, et al. patent, discussed above, the Tm and Tg properties of the materials used in the present invention are not dependent on being in osmotic equilibrium in the body (i.e., Tm and Tg do not change in the presence of eye liquids). Although there are many different polymer structures which can form the desired crystalline regions, the preferred embodiments of the present invention include side chain crystalline-inducing polymers. The more preferred embodiments are the acrylic family polymers With long side chain alkyls (more than twelve carbons) as the crystalline-inducing groups.
It is well known to whose who are skilled in the art that as the length of the side chain of an acrylic ester monomer increases, the Tg of the homopolymer decreases. For example, CHz = CH(R) - COO R' Where R = H or CH3; and R' = alkyl groups, such as CH3-(CHa)"- , n = 0 to 19.
When R = CH3, and R' is the alkyl group where n increases from 0 to 17, then Tg of the homopolymer of the respective monomer decreases. The trend is illustrated in Table 1. Additionally, as n increases from 11 (lauryl methacrylate) to 17 (stearyl.
methacrylate), side chain crystallinity starts to form. For example, polystearyl methacrylate (n = 17 in R') has a side chain crystalline formation with a Tm of about 36°C.
Table 1. Physical Properties of Methacrylate Homopolymers in Literature~l~
n Polymer Name Tg (C) Tm (C) 0 Poly(methyl methacrylate)105 N/A
1 Poly(ethyl methacrylate) 65 N/A
3 Poly(butyl methacrylate) 20 N/A
11 Poly(lauryl methacrylate)-65 N/A
17 Poly(stearyl methacxylate)-100 36 Note: (1) Herman F. Mark, et al, Encyclopedia of Polymer Science and Engineering, Volume l, Pages 234 - 299, John Wiley & Sons, Inc. 1985.
The melting temperature, or Tm, is a characteristic of crystalline or semi-crystalline polymers. Melting may be observed visually in some materials, as the temperature increases when a material changes from white or opaque to hazy or transparent. Before the advent of sophisticated instrumental methods, melting temperatures were determined by viewing the melting polymer under a microscope between crossed polarizers. Dilatometry, where volume changes are measured, is another method for finding Tm. The use of a differential scanning calorimeter (DSC) is a popular method for examining the melting transition and is used for the determination of the Tm in the present invention.
Polystearyl methacrylate (SMA) is a white solid polymer at room temperature in its crystalline form. However, polystearyl methacrylate is found to be transparent when it is warmed up to a temperature higher than its melting temperature and its side chain crystalline structure melts. Because polystearyl methacrylate has a Tg of about -100°C, it is an elastomer after it melts. These dual thermodynamic properties, one corresponding to Tg and another corresponding to Tm, are required for the crystalline polymers in the present invention.
However, the homopolymer of stearyl methacrylate is tacky after it melts. This tackiness can be reduced by copolymerization with other monomers, such as methyl methacrylate (MMA). This tackiness can be further reduced by adding and increasing the amount of crosslinkers. Crosslinkers (for example, EGDMA, ethylene glycol dimethacrylate) can also improve the elasticity of the crystalline polymer, and therefore increase its capability for recovery from a deformed state. Table 2 is a summary of examples for the present invention.
Table 2. Examples . for Compositions and Their Properties of the Present Invention No.SMA % MMA % (by EGDMA% (by RefractiveTm (C) Tg wei ht wei ht wei ht ~l~ Index 35C (C) 1 100% 0% 0% 1.470 34 -100 Z
2 95% 5% 0.1% 1.470 26 3 85% 15% 0.1% 1.473 17 4 80% 20% 0% 1.473 18 5 80% 20% 0.04% 1.473 17 6 60% 40% 0.04% 1.477 10 -17 7 50% 50% 0.04% 1.480 Note 17 (4) Note: (1) EGDMA is Ethylene Glycol Dimethacrylate. The percentage of EGDMA
is based on 100% of monomers, i.e. (SMA + MMA) (2) Tg of -100°C is a literature value. The literature value of Tm for poly(stearyl methacrylate) is -36°C
(3) Composition No 4 contains 1% of W absorber, 2-(2'-hydroxy-5'-acryloxypropylenephenyl)-2H-benzotriazole 2.0 (4) Tm was not observed on DSC experiments -12_ Examples of polymeric materials which may be used in the ophthalmic devices of the present invention include polymers, homopolymers, cross-linked polymers and copolymers of silicones, acrylic esters, polyurethane, hydrocarbon polymers, and combinations thereof Specific materials include, for example, acrylic esters, copolymers of long chain methacrylates with short chain methacrylates (such as copolymers of polystearylmethacrylate with polymethylmethacrylate), and side-chain crystalizible polymers which comprise an acrylic ester of the formula:
wherein X is H or a C1-C6 alkyl, and R is a linear Clo-C26 alkyl.
One of the applications for the present invention is to provide an alternative and superior method for implanting an IOL of various designs through a small 1 S incision. The IOL can be phakic or aphalcic and it may be located in the posterior chamber of the eye or in the anterior chamber of the eye, or within the cornea, or a combination of them. Samples for the IOL design of the present invention are illustrated in, but not limited to, Figures 1-10. Of particular interest, is the full size lens, such as the one in Figure 5. A full size lens has a diameter in the range from about 8 to about 11 mm and a central lens thickness in the range from about 2 to about 5 mm. The present invention can allow such a full size lens to be implanted through a small incision. Because the IOL nearly fills the whole capsular bag, it may be possible that such a full size lens can inhibit secondary cataract formation.
One feature of the crystalline polymers used in the present invention is that they provide materials with a very wide range of properties, such as hardness (or softness) as measured by Durometers. Because Tg and Tm are two distinctly different thermodynamic transitions in polymer properties, it is possible to provide very soft materials by the present invention. For instance, example 1 in Table 2 has a melting point of 34°C corresponding to the crystalline structure formed by the side chain stearyl group, and a Tg of -100°C corresponding mainly to the long polymeric backbone structure. At room temperature, it is a hard white solid. However, when the copolymer is heated up to the melting temperature or higher, it becomes transparent after all crystalline side chains have melted. It also becomes very soft because the melted side chain stearyl groups function as a plasticizer or as if it were a "solvent". This low hardness can be a very useful property in the case of a full size lens design which may possibly restore accommodation for the presbyopia patients.
The "fluid" property due to the melted crystalline side chain is also the driving force in the present invention for the ophthalmic device to adapt to a new configuration shaped by the surrounding tissue. On the other hand, the elasticity due to the long chain of the polymer backbone and the crosslinking is the driving force for the shape recovery of the ophthalmic devices from the deformed shape to the pre-deformed shape. This crystalline - fluid interphase change of the long side chain provides a novel mechanism for achieving the goals of the present invention.
In order to understand the way the present invention is practiced, an intraocular lens (IOL) is used as an example. The IOL of the present invention is made from crystalline polymeric materials having the following properties:
(1) Crystalline melting temperature, Tn.,, in the range from about 0°C
to about 37°C, preferably from about 15°C to about 30°C.
(2) Glass transition temperature, T~, in the range from about -100°C to about 20°C, preferably from about -100°C to about -17 °C.
In all cases, Tg should not be higher than room temperature.
(3) Being optically transparent at or above the Tm. On the other hand, it is not necessary for the IOL made from the crystalline polymeric mateuial to be transparent below the Tm. It may not be a requirement for non-lens related applications that the crystalline polymer be transparent at any given temperature. FurtherW ore, other additives may be added to the crystalline polymer composition as required by the specific circumstances. For example, an ultraviolet (UV) absorber may be incorporated into lenses for the protection of human eyes from damage caused by UV light exposure. Another example is that barium sulfate may be added to a non-lens device for rendering it radio-opaque. Therefore, the device can be examined by a radiological method if needed.
The method for implanting the IOL (or other ophthalmic device) of the present invention includes the following steps:
(a) Warm the IOL to a temperature at or above the Tm, then deform the IOL into a shape, such as folded, rolled, and/or stretched at the same time, which can be implanted through a small incision into the eye. The ideal size for the incision is from about 2 to about 4 mm.
(b) Cool down the deformed IOL to a temperature below the Tm while the deforming force, such as folding, rolling, clamping, and/or stretching, etc., is still applied to tile IOL. After removing the deforming force, the cooled IOL will remain in its deformed shape.
(c) Implant the deformed lens at a temperature below the Tm through a small incision into the eye so that the lens remains in the solid deformed form and that it is relatively easy to insert into the soft tissue opening.
(d) When warmed up to and above the Tm by the body temperature of the eye, the deformed IOL will return to its pre-deformed shape, providing the desirable optical power and resolution for the patient.
EXAMPLES
Example 1. Lens Preparation To a round-bottomed flask, equipped with a magnetic stirnng bar, is added a mixture of 4.75 grams of SMA, 0.25 gram of MMA, 5 microliters of ethylene glycol dimethacrylate, and 0.01 gram of benzoyl peroxide. The flaslc is purged with nitrogen gas for about 2 minutes and subsequently maintained under positive nitrogen atmosphere. The reaction mixture is then heated to about 110°C
in a silicone oil bath while stirnng. After approximately 5 minutes, evolving of gas is observed, indicating decomposition of the benzoyl peroxide initiator to form benzoyloxy radicals initiating the polymerization reaction. After approximately 5 minutes from when the initial gas evolution is first observed, the reaction mixture becomes obviously viscous, indicating the polymerization and crosslinking reaction has occurred. Before the reaction mixture becomes too viscous to be poured out from the flaslc, a small amount of the mixture is taken out with a spatula and is transferred into an IOL mold. The mold is then closed and is placed into a preheated oven at 110°C for 16 hours. After the mold is taken out from the oven and cools down to the room temperature, the mold is placed in a refrigerator for about 2 hours.
The mold is then opened. A white or translucent solid IOL is carefully removed from the mold.
The IOL prepared from above procedure is placed in. warm water (37°C, for example), and the IOL gradually changes from the white or translucent solid to a transparent soft lens. This soft lens can be stretched to reduce the intersectional area in the warm water bath. The stretched IOL is then removed from the warm water bath and allowed to cool down to the room temperature. The stretched IOL
retains its stretched shape after about 3 minutes. The stretched IOL gradually changes from transparent to translucent and then to white hard solid. If an ice water bath is used instead of room temperature air, this "freezing" process can be completed in about 1 minute.
When the stretched IOL is warmed again in a 37°C saline solution or water bath, it returns to its pre-stretched shape in about 1 minute. The recovered lens is transparent and soft as long as the temperature is maintained at 37°C
or higher.
Other compositions in Table 2 are prepared in a similar manner. When a UV
absorber is used, it can be added to the initial reaction mixture before the heating step. In addition, ice water is preferably used for these compositions with the Tm less than 20°C for the freezing step.
Example 2. Rod Preparation A mixture of 5 grams of stearyl methacrylate and 0.01 gram of benzoyl peroxide is warmed to about 40°C so that it becomes a homogenous solution. The mixture is degassed and refilled with nitrogen. After the mixture is transferred into a polypropylene tube with an internal diameter of about 1 mm and with one end pre-sealed by heating, the open end is also sealed by heating. The sealed tube is about 2 inches long and is placed in an oven at 110°C fox 16 hours. At the end of the reaction, the oven is cooled down to room temperature. Then both ends of the sealed tube are cut off with a razor. The white solid rod inside the tube can be pushed out from the tube with a metal wire.
The white solid rod prepared from above procedure can be warmed up in water bath (45°C for example). It becomes transparent and soft almost instantly.
The soft rod is stretched in the water bath until the diameter of the rod becomes about 0.3 mm. The stretched rod is then lifted from the warm water bath to the room temperature air. It becomes solid in about 1 minute and retains its stretched shape as long as the temperature remains below its melting temperature.
When the stretched rod is warmed up in a saline solution, such as 37°C, it becomes soft and its diameter changes back to 1 mm in about 1 minute.
is based on 100% of monomers, i.e. (SMA + MMA) (2) Tg of -100°C is a literature value. The literature value of Tm for poly(stearyl methacrylate) is -36°C
(3) Composition No 4 contains 1% of W absorber, 2-(2'-hydroxy-5'-acryloxypropylenephenyl)-2H-benzotriazole 2.0 (4) Tm was not observed on DSC experiments -12_ Examples of polymeric materials which may be used in the ophthalmic devices of the present invention include polymers, homopolymers, cross-linked polymers and copolymers of silicones, acrylic esters, polyurethane, hydrocarbon polymers, and combinations thereof Specific materials include, for example, acrylic esters, copolymers of long chain methacrylates with short chain methacrylates (such as copolymers of polystearylmethacrylate with polymethylmethacrylate), and side-chain crystalizible polymers which comprise an acrylic ester of the formula:
wherein X is H or a C1-C6 alkyl, and R is a linear Clo-C26 alkyl.
One of the applications for the present invention is to provide an alternative and superior method for implanting an IOL of various designs through a small 1 S incision. The IOL can be phakic or aphalcic and it may be located in the posterior chamber of the eye or in the anterior chamber of the eye, or within the cornea, or a combination of them. Samples for the IOL design of the present invention are illustrated in, but not limited to, Figures 1-10. Of particular interest, is the full size lens, such as the one in Figure 5. A full size lens has a diameter in the range from about 8 to about 11 mm and a central lens thickness in the range from about 2 to about 5 mm. The present invention can allow such a full size lens to be implanted through a small incision. Because the IOL nearly fills the whole capsular bag, it may be possible that such a full size lens can inhibit secondary cataract formation.
One feature of the crystalline polymers used in the present invention is that they provide materials with a very wide range of properties, such as hardness (or softness) as measured by Durometers. Because Tg and Tm are two distinctly different thermodynamic transitions in polymer properties, it is possible to provide very soft materials by the present invention. For instance, example 1 in Table 2 has a melting point of 34°C corresponding to the crystalline structure formed by the side chain stearyl group, and a Tg of -100°C corresponding mainly to the long polymeric backbone structure. At room temperature, it is a hard white solid. However, when the copolymer is heated up to the melting temperature or higher, it becomes transparent after all crystalline side chains have melted. It also becomes very soft because the melted side chain stearyl groups function as a plasticizer or as if it were a "solvent". This low hardness can be a very useful property in the case of a full size lens design which may possibly restore accommodation for the presbyopia patients.
The "fluid" property due to the melted crystalline side chain is also the driving force in the present invention for the ophthalmic device to adapt to a new configuration shaped by the surrounding tissue. On the other hand, the elasticity due to the long chain of the polymer backbone and the crosslinking is the driving force for the shape recovery of the ophthalmic devices from the deformed shape to the pre-deformed shape. This crystalline - fluid interphase change of the long side chain provides a novel mechanism for achieving the goals of the present invention.
In order to understand the way the present invention is practiced, an intraocular lens (IOL) is used as an example. The IOL of the present invention is made from crystalline polymeric materials having the following properties:
(1) Crystalline melting temperature, Tn.,, in the range from about 0°C
to about 37°C, preferably from about 15°C to about 30°C.
(2) Glass transition temperature, T~, in the range from about -100°C to about 20°C, preferably from about -100°C to about -17 °C.
In all cases, Tg should not be higher than room temperature.
(3) Being optically transparent at or above the Tm. On the other hand, it is not necessary for the IOL made from the crystalline polymeric mateuial to be transparent below the Tm. It may not be a requirement for non-lens related applications that the crystalline polymer be transparent at any given temperature. FurtherW ore, other additives may be added to the crystalline polymer composition as required by the specific circumstances. For example, an ultraviolet (UV) absorber may be incorporated into lenses for the protection of human eyes from damage caused by UV light exposure. Another example is that barium sulfate may be added to a non-lens device for rendering it radio-opaque. Therefore, the device can be examined by a radiological method if needed.
The method for implanting the IOL (or other ophthalmic device) of the present invention includes the following steps:
(a) Warm the IOL to a temperature at or above the Tm, then deform the IOL into a shape, such as folded, rolled, and/or stretched at the same time, which can be implanted through a small incision into the eye. The ideal size for the incision is from about 2 to about 4 mm.
(b) Cool down the deformed IOL to a temperature below the Tm while the deforming force, such as folding, rolling, clamping, and/or stretching, etc., is still applied to tile IOL. After removing the deforming force, the cooled IOL will remain in its deformed shape.
(c) Implant the deformed lens at a temperature below the Tm through a small incision into the eye so that the lens remains in the solid deformed form and that it is relatively easy to insert into the soft tissue opening.
(d) When warmed up to and above the Tm by the body temperature of the eye, the deformed IOL will return to its pre-deformed shape, providing the desirable optical power and resolution for the patient.
EXAMPLES
Example 1. Lens Preparation To a round-bottomed flask, equipped with a magnetic stirnng bar, is added a mixture of 4.75 grams of SMA, 0.25 gram of MMA, 5 microliters of ethylene glycol dimethacrylate, and 0.01 gram of benzoyl peroxide. The flaslc is purged with nitrogen gas for about 2 minutes and subsequently maintained under positive nitrogen atmosphere. The reaction mixture is then heated to about 110°C
in a silicone oil bath while stirnng. After approximately 5 minutes, evolving of gas is observed, indicating decomposition of the benzoyl peroxide initiator to form benzoyloxy radicals initiating the polymerization reaction. After approximately 5 minutes from when the initial gas evolution is first observed, the reaction mixture becomes obviously viscous, indicating the polymerization and crosslinking reaction has occurred. Before the reaction mixture becomes too viscous to be poured out from the flaslc, a small amount of the mixture is taken out with a spatula and is transferred into an IOL mold. The mold is then closed and is placed into a preheated oven at 110°C for 16 hours. After the mold is taken out from the oven and cools down to the room temperature, the mold is placed in a refrigerator for about 2 hours.
The mold is then opened. A white or translucent solid IOL is carefully removed from the mold.
The IOL prepared from above procedure is placed in. warm water (37°C, for example), and the IOL gradually changes from the white or translucent solid to a transparent soft lens. This soft lens can be stretched to reduce the intersectional area in the warm water bath. The stretched IOL is then removed from the warm water bath and allowed to cool down to the room temperature. The stretched IOL
retains its stretched shape after about 3 minutes. The stretched IOL gradually changes from transparent to translucent and then to white hard solid. If an ice water bath is used instead of room temperature air, this "freezing" process can be completed in about 1 minute.
When the stretched IOL is warmed again in a 37°C saline solution or water bath, it returns to its pre-stretched shape in about 1 minute. The recovered lens is transparent and soft as long as the temperature is maintained at 37°C
or higher.
Other compositions in Table 2 are prepared in a similar manner. When a UV
absorber is used, it can be added to the initial reaction mixture before the heating step. In addition, ice water is preferably used for these compositions with the Tm less than 20°C for the freezing step.
Example 2. Rod Preparation A mixture of 5 grams of stearyl methacrylate and 0.01 gram of benzoyl peroxide is warmed to about 40°C so that it becomes a homogenous solution. The mixture is degassed and refilled with nitrogen. After the mixture is transferred into a polypropylene tube with an internal diameter of about 1 mm and with one end pre-sealed by heating, the open end is also sealed by heating. The sealed tube is about 2 inches long and is placed in an oven at 110°C fox 16 hours. At the end of the reaction, the oven is cooled down to room temperature. Then both ends of the sealed tube are cut off with a razor. The white solid rod inside the tube can be pushed out from the tube with a metal wire.
The white solid rod prepared from above procedure can be warmed up in water bath (45°C for example). It becomes transparent and soft almost instantly.
The soft rod is stretched in the water bath until the diameter of the rod becomes about 0.3 mm. The stretched rod is then lifted from the warm water bath to the room temperature air. It becomes solid in about 1 minute and retains its stretched shape as long as the temperature remains below its melting temperature.
When the stretched rod is warmed up in a saline solution, such as 37°C, it becomes soft and its diameter changes back to 1 mm in about 1 minute.
Claims (27)
1. An ophthalmic device suitable for implantation through an incision in the human eye, made from a composition containing a crystalline or a semi-crystalline polymeric material having the following properties:
(a) a glass transition temperature (T g) in the range from about -100°C
to about 20°C;
(b) a melting temperature (T m) in the range from about 0°C to about 37°C; and (c) wherein said glass transition temperature (T g) of the polymeric material is lower than said melting temperature (T m) for the composition.
(a) a glass transition temperature (T g) in the range from about -100°C
to about 20°C;
(b) a melting temperature (T m) in the range from about 0°C to about 37°C; and (c) wherein said glass transition temperature (T g) of the polymeric material is lower than said melting temperature (T m) for the composition.
2. A method for implantation through an incision in the eye of an ophthalmic device made from a composition containing a crystalline or a semi-crystalline polymeric material with a T g in the range from about -100°C to about 20°C and a T m in the range from about 0°C to about 37°C, comprising the steps of:
(a) warming up said ophthalmic device to or above its T m, then deforming said ophthalmic device into a deformed shape which can be implanted through an incision where the size of said incision is smaller than the said ophthalmic device in its intended use condition;
(b) cooling down said deformed ophthalmic device to a temperature below the T m, such that said ophthalmic device remains in said deformed shape;
(c) implanting said deformed ophthalmic device at a temperature below the T m through said incision in the eye; and (d) warming up said ophthalmic device to and above its T m by the body temperature of the eye, whereupon said ophthalmic device changes into a shape suitable for its intended use.
(a) warming up said ophthalmic device to or above its T m, then deforming said ophthalmic device into a deformed shape which can be implanted through an incision where the size of said incision is smaller than the said ophthalmic device in its intended use condition;
(b) cooling down said deformed ophthalmic device to a temperature below the T m, such that said ophthalmic device remains in said deformed shape;
(c) implanting said deformed ophthalmic device at a temperature below the T m through said incision in the eye; and (d) warming up said ophthalmic device to and above its T m by the body temperature of the eye, whereupon said ophthalmic device changes into a shape suitable for its intended use.
3. The ophthalmic device of Claim 1 selected from intraocular lenses, corneal inlays, ocular drug delivery devices, and implants for reducing intraocular pressure.
4. The ophthalmic device of Claim 1 wherein the polymeric material is selected from polymers, homopolyners, cross-linked polymers and copolymers of silicones, acrylic esters, polyurethane, hydrocarbon polymers, and combinations thereof.
5. The ophthalmic device of Claim 1 wherein the polymeric material is an acrylic ester.
6. The ophthalmic device of Claim 5 wherein the polymeric material is a copolymer of polystearylinethacrylate and polymethyl methacrylate.
7. The ophthalmic device of Claim 5 wherein the polymeric material is a side-chain crystallizable polymer which comprises an acrylic ester of the formula:
wherein X is H or a C1 - C6 alkyl; and R is a linear C10 - C26 alkyl.
wherein X is H or a C1 - C6 alkyl; and R is a linear C10 - C26 alkyl.
8. The ophthalmic device of Claim 3 in the form of an intraocular lens.
9. The ophthalmic device of Claim 8 wherein said intraocular lens is a full size lens
10. The ophthalmic device of Claim 9 wherein said full size lens has a diameter of from about 8 to about 11 mm and central lens thickness of from about 2 to about 5 mm.
11. The ophthalmic device of Claim 9 wherein said full size lens is an accommodative lens
12. The ophthalmic device of Claim 8 wherein the polymeric material is optically transparent at or above T m
13. The ophthalmic device of Claim 12 wherein the polymeric material has a T m of from about 15°C to about 30°C.
14. The ophthalmic device of Claim 13 wherein the polymeric material has a T g of from about -100°C to about -17°C.
15. The method according to Claim 2 wherein the ophthalmic device is selected from intraocular lenses, corneal inlays, ocular drug delivery devices, and implants for reducing intraocular pressure.
16. The method according to Claim 15 wherein the ophthalmic device is an intraocular lens.
17. The method according to Claim 16 wherein said intraocular lens is a full size lens.
18. The method according to Claim 17 wherein said full size lens has a diameter of from about 8 to about 11 mm and central lens thickness of from about 2 to abut 5 mm.
19. The method according to Claim 17 wherein said full size lens is an accommodative lens.
20. The method according to Claim 16 wherein the length of the incision is from about 2 to about 4 mm.
21. The method according to Claim 15 wherein the polymeric material is selected from polymers, homopolymers, cross-linked polymers and copolymers of silicones, acrylic esters, polyurethane, hydrocarbon polymers, and combinations thereof.
22. The method according to Claim 21 wherein the polymeric material is an acrylic ester.
23. The method according to Claim 22 wherein the polymeric material is a copolymer of polystearylmethacrylate and polymethylmethacrylate.
24. The method according to Claim 22 wherein the polymeric material is a side-chain crystallizable polymer which comprises an acrylic ester of the formula:
wherein X is H or a C1-C6 alkyl; and R is a linear C10-C26 alkyl.
wherein X is H or a C1-C6 alkyl; and R is a linear C10-C26 alkyl.
25. The method according to Claim 16 wherein the polymeric material is optically transparent at or above T m.
26. The method according to Claim 25 wherein the polymeric material has a T m of from about 15°C to about 30°C.
27. The method according to Claim 26 wherein the polymeric material has a T g of from about -100°C to about -17°C.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20619700P | 2000-05-22 | 2000-05-22 | |
US60/206,197 | 2000-05-22 | ||
US09/796,174 US6679605B2 (en) | 2000-05-22 | 2001-02-28 | Crystalline polymeric compositions for ophthalmic devices |
US09/796,174 | 2001-02-28 | ||
PCT/US2001/008466 WO2001089816A1 (en) | 2000-05-22 | 2001-03-16 | Crystalline polymeric compositions for ophthalmic devices |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2407958A1 true CA2407958A1 (en) | 2001-11-29 |
Family
ID=26901143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002407958A Abandoned CA2407958A1 (en) | 2000-05-22 | 2001-03-16 | Crystalline polymeric compositions for ophthalmic devices |
Country Status (11)
Country | Link |
---|---|
US (1) | US6679605B2 (en) |
EP (1) | EP1289740B1 (en) |
JP (1) | JP2003534070A (en) |
AT (1) | ATE301542T1 (en) |
AU (1) | AU2001243692A1 (en) |
BR (1) | BR0111056A (en) |
CA (1) | CA2407958A1 (en) |
DE (1) | DE60112570T2 (en) |
ES (1) | ES2247081T3 (en) |
MX (1) | MXPA02011564A (en) |
WO (1) | WO2001089816A1 (en) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6786928B2 (en) | 1997-08-20 | 2004-09-07 | Thinoptx, Inc. | Small incision lens |
US6800091B2 (en) * | 1997-08-20 | 2004-10-05 | Thinoptx, Inc. | Method of using a small incision lens |
US20060238702A1 (en) | 1999-04-30 | 2006-10-26 | Advanced Medical Optics, Inc. | Ophthalmic lens combinations |
US7763069B2 (en) | 2002-01-14 | 2010-07-27 | Abbott Medical Optics Inc. | Accommodating intraocular lens with outer support structure |
US20040030062A1 (en) * | 2002-05-02 | 2004-02-12 | Mather Patrick T. | Castable shape memory polymers |
US20030223954A1 (en) * | 2002-05-31 | 2003-12-04 | Ruscio Dominic V. | Polymeric materials for use as photoablatable inlays |
CA2501549C (en) * | 2002-10-11 | 2011-08-30 | University Of Connecticut | Blends of amorphous and semicrystalline polymers having shape memory properties |
US7794494B2 (en) * | 2002-10-11 | 2010-09-14 | Boston Scientific Scimed, Inc. | Implantable medical devices |
EP1554328B1 (en) * | 2002-10-11 | 2011-02-23 | The University of Connecticut | Shape memory polymers based on semicrystalline thermoplastic polyurethanes bearing nanostructured hard segments |
US7524914B2 (en) | 2002-10-11 | 2009-04-28 | The University Of Connecticut | Shape memory polymers based on semicrystalline thermoplastic polyurethanes bearing nanostructured hard segments |
JP4530989B2 (en) * | 2002-10-11 | 2010-08-25 | ユニバーシティ オブ コネチカット | Shape memory polymer |
US7976936B2 (en) * | 2002-10-11 | 2011-07-12 | University Of Connecticut | Endoprostheses |
US7662180B2 (en) | 2002-12-05 | 2010-02-16 | Abbott Medical Optics Inc. | Accommodating intraocular lens and method of manufacture thereof |
WO2004066870A2 (en) * | 2003-01-27 | 2004-08-12 | Restorvision Ltd | Combined iol and scleral implants and method of use |
US20110098790A1 (en) * | 2009-10-26 | 2011-04-28 | Albert Daxer | Methods for treating corneal disease |
WO2005048882A1 (en) | 2003-11-18 | 2005-06-02 | Medennium, Inc. | Accommodative intraocular lens and method of implantation |
US20050131535A1 (en) | 2003-12-15 | 2005-06-16 | Randall Woods | Intraocular lens implant having posterior bendable optic |
WO2005103201A1 (en) * | 2004-03-31 | 2005-11-03 | University Of Connecticut | Shape memory main-chain smectic-c elastomers |
US20050283164A1 (en) * | 2004-06-18 | 2005-12-22 | Henry Wu | Apparatus and method for implanting intraocular lens through a small incision |
US8133274B2 (en) * | 2004-06-18 | 2012-03-13 | Medennium, Inc. | Photochromic intraocular lenses and methods of making the same |
US7563388B2 (en) * | 2004-08-27 | 2009-07-21 | The University Of Connecticut | Crosslinked liquid crystalline polymer, method for the preparation thereof, and articles derived therefrom |
EP1844097A2 (en) * | 2004-12-10 | 2007-10-17 | University of Connecticut | Shape memory polymer orthodontic appliances, and methods of making and using the same |
US8043361B2 (en) * | 2004-12-10 | 2011-10-25 | Boston Scientific Scimed, Inc. | Implantable medical devices, and methods of delivering the same |
US20060173539A1 (en) * | 2005-01-31 | 2006-08-03 | Yichieh Shiuey | Corneal implants and methods and systems for placement |
US9999497B2 (en) | 2005-01-31 | 2018-06-19 | Yichieh Shiuey | Corneal implants and methods and systems for placement |
US9636213B2 (en) | 2005-09-30 | 2017-05-02 | Abbott Medical Optics Inc. | Deformable intraocular lenses and lens systems |
US8241355B2 (en) * | 2005-10-28 | 2012-08-14 | Abbott Medical Optics Inc. | Haptic for accommodating intraocular lens |
MX2008011680A (en) * | 2006-03-16 | 2008-12-10 | Daxer Albert | Structural member. |
US8377125B2 (en) | 2006-04-05 | 2013-02-19 | Anew Optics, Inc. | Intraocular lens with accommodation |
ES2523690T3 (en) | 2006-05-23 | 2014-11-28 | Daxer, Albert | Corneal implant for the correction of vision defects of the human eye |
US20080097596A1 (en) * | 2006-10-18 | 2008-04-24 | Christ F Richard | Injection of anti-presbyopia corrective element precursor |
US8399007B2 (en) * | 2006-12-05 | 2013-03-19 | Landec Corporation | Method for formulating a controlled-release pharmaceutical formulation |
US20090263346A1 (en) * | 2006-12-05 | 2009-10-22 | David Taft | Systems and methods for delivery of drugs |
US20090246155A1 (en) * | 2006-12-05 | 2009-10-01 | Landec Corporation | Compositions and methods for personal care |
US20100004124A1 (en) * | 2006-12-05 | 2010-01-07 | David Taft | Systems and methods for delivery of materials for agriculture and aquaculture |
US20100210792A1 (en) * | 2006-12-05 | 2010-08-19 | David Taft | Drug delivery |
US20080161914A1 (en) | 2006-12-29 | 2008-07-03 | Advanced Medical Optics, Inc. | Pre-stressed haptic for accommodating intraocular lens |
US8114883B2 (en) * | 2007-12-04 | 2012-02-14 | Landec Corporation | Polymer formulations for delivery of bioactive materials |
WO2009079559A1 (en) * | 2007-12-17 | 2009-06-25 | University Of Florida Research Foundation, Inc. | Dry eye treatment by puncta plugs |
US8480734B2 (en) | 2007-12-27 | 2013-07-09 | Anew Optics, Inc. | Intraocular lens with accommodation |
US8034108B2 (en) | 2008-03-28 | 2011-10-11 | Abbott Medical Optics Inc. | Intraocular lens having a haptic that includes a cap |
EP2361060A4 (en) | 2008-11-26 | 2014-02-26 | Anew Optics Inc | Haptic devices for intraocular lens |
US10010405B2 (en) | 2008-11-26 | 2018-07-03 | Anew Aol Technologies, Inc. | Haptic devices for intraocular lens |
JP5890182B2 (en) | 2009-02-12 | 2016-03-22 | インセプト エルエルシー | Drug delivery with hydrogel plugs |
US20120088659A1 (en) * | 2009-06-04 | 2012-04-12 | Landec Corporation | Compositions and Methods for Delivery of Materials |
US20120082709A1 (en) * | 2009-06-11 | 2012-04-05 | Landec Corporation | Compositions and methods for delivery of materials |
EP2445446B1 (en) | 2009-06-26 | 2019-01-09 | Johnson & Johnson Surgical Vision, Inc. | Accommodating intraocular lenses |
US8343217B2 (en) | 2009-08-03 | 2013-01-01 | Abbott Medical Optics Inc. | Intraocular lens and methods for providing accommodative vision |
EP2542183A4 (en) * | 2010-03-04 | 2014-04-30 | Perfect Ip Llc | System for forming and modifying lenses and lenses formed thereby |
EP2621405B8 (en) | 2010-09-30 | 2019-01-09 | KeraMed, Inc. | Reversibly deformable artificial cornea |
US9414908B2 (en) * | 2011-04-18 | 2016-08-16 | Parrot Drones | Liquid formulation for ophtalmic devices |
ES2666857T3 (en) | 2011-07-18 | 2018-05-08 | Mor-Research Applications Ltd. | A device to adjust intraocular pressure |
US10226417B2 (en) | 2011-09-16 | 2019-03-12 | Peter Jarrett | Drug delivery systems and applications |
US9084674B2 (en) | 2012-05-02 | 2015-07-21 | Abbott Medical Optics Inc. | Intraocular lens with shape changing capability to provide enhanced accomodation and visual acuity |
US9974646B2 (en) | 2012-09-05 | 2018-05-22 | University Of Miami | Keratoprosthesis, and system and method of corneal repair using same |
US20140277438A1 (en) | 2013-03-14 | 2014-09-18 | Medennium, Inc. | Crystalline polymeric compositions for ophthalmic devices |
EP3681438A1 (en) | 2017-09-11 | 2020-07-22 | AMO Groningen B.V. | Methods and apparatuses to increase intraocular lenses positional stability |
WO2019055477A2 (en) | 2017-09-14 | 2019-03-21 | Board Of Trustees Of The University Of Illinois | Devices, systems, and methods for vision restoration |
JP7102735B2 (en) * | 2018-01-09 | 2022-07-20 | 株式会社ニデック | Intraocular lens insertion device and intraocular lens insertion system |
BR112021026265A2 (en) | 2019-06-27 | 2022-06-14 | Layerbio Inc | Eye device delivery methods and systems |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH512980A (en) * | 1969-01-20 | 1971-09-30 | Ceskoslovenska Akademie Ved | Process for the production of rotationally symmetrical objects by centrifugal casting |
CS175082B1 (en) * | 1974-08-28 | 1977-04-29 | ||
CS179567B1 (en) * | 1974-11-25 | 1977-11-30 | Vladimir Stoy | Ionogennic hydrophilic in water insoluble gels based on partial saponificated polymers or copolymers acrylonitrile and method of preparing them |
US4173606A (en) * | 1975-07-14 | 1979-11-06 | Ceskoslovenska Akademie Ved. | Method of manufacturing shaped articles from crystalline acrylonitrile polymers and copolymers |
US4556998A (en) | 1983-08-04 | 1985-12-10 | Siepser Steven B | Artificial intraocular lenses and method for their surgical implantation |
US5041133A (en) * | 1984-04-11 | 1991-08-20 | Pharmacia Ab | Intraocular implant |
US4681585A (en) * | 1984-04-11 | 1987-07-21 | Intermedics Intraocular, Inc. | Intraocular implant |
US4731079A (en) | 1986-11-26 | 1988-03-15 | Kingston Technologies, Inc. | Intraocular lenses |
US4834750A (en) * | 1987-09-17 | 1989-05-30 | Ioptex Research, Inc. | Deformable-elastic intraocular lens |
US4813954A (en) | 1987-10-09 | 1989-03-21 | Siepser Steven B | Compression, deformation, dehydration method of fabrication and implantation of an expansile, hydrogel intraocular lens |
US5147394A (en) | 1987-10-09 | 1992-09-15 | Siepser Steven B | High refractive index polymeric compositions suitable for use as expansile hydrogel intraocular lenses |
US5026393A (en) | 1988-01-20 | 1991-06-25 | Mackool Richard J | Method of implanting an intraocular lens in a human eye and intraocular lens for same |
US5037178A (en) * | 1988-12-22 | 1991-08-06 | Kingston Technologies, L.P. | Amorphous memory polymer alignment device |
US4993936A (en) | 1989-04-17 | 1991-02-19 | Siepser Steven B | Apparatus for compressing, deforming and dehydrating expansile, hydrogel intraocular lens |
US5171267A (en) * | 1989-08-31 | 1992-12-15 | The Board Of Regents Of The University Of Washington | Surface-modified self-passivating intraocular lenses |
US5269813A (en) | 1990-06-12 | 1993-12-14 | Menicon Co., Ltd. | Material for one-piece intraocular lenses |
US5290892A (en) | 1990-11-07 | 1994-03-01 | Nestle S.A. | Flexible intraocular lenses made from high refractive index polymers |
US5210111A (en) | 1991-08-22 | 1993-05-11 | Ciba-Geigy Corporation | Crosslinked hydrogels derived from hydrophilic polymer backbones |
US5469867A (en) * | 1992-09-02 | 1995-11-28 | Landec Corporation | Cast-in place thermoplastic channel occluder |
US5331073A (en) | 1992-11-09 | 1994-07-19 | Allergan, Inc. | Polymeric compositions and intraocular lenses made from same |
US5603774A (en) | 1993-09-27 | 1997-02-18 | Alcon Laboratories, Inc. | Method for reducing tackiness of soft acrylic polymers |
CZ282355B6 (en) * | 1994-12-01 | 1997-07-16 | Vladimír Ing. Csc. Stoy | Implantable ophthalmic lens, process of its production and a mould for making the same |
US5556400A (en) | 1994-12-27 | 1996-09-17 | Tunis; Scott W. | Methods of preparing and inserting flexible intraocular lenses and a configuration for flexible intraocular lenses |
AU696001B2 (en) | 1995-06-07 | 1998-08-27 | Alcon Laboratories, Inc. | Improved high refractive index ophthalmic lens materials |
US5777034A (en) | 1995-12-28 | 1998-07-07 | Rohm And Haas Company | Methacrylate resin blends |
US5922821A (en) | 1996-08-09 | 1999-07-13 | Alcon Laboratories, Inc. | Ophthalmic lens polymers |
US5891931A (en) | 1997-08-07 | 1999-04-06 | Alcon Laboratories, Inc. | Method of preparing foldable high refractive index acrylic ophthalmic device materials |
US6030416A (en) | 1998-02-13 | 2000-02-29 | Pharmacia & Upjohn Ab | Medical implants of stretch-crystallizable elastomers and methods of implantation |
AU760960B2 (en) * | 1998-10-29 | 2003-05-22 | Advanced Medical Optics, Inc. | Intraocular lenses made from polymeric compositions |
WO2000057213A1 (en) * | 1999-03-23 | 2000-09-28 | Medennium, Inc. | Polymeric material compositions and intraocular lenses made from same |
US6234175B1 (en) | 1999-03-23 | 2001-05-22 | Medennium, Inc. | Smart ocular plug design and method of insertion for punctal and intracanalicular implants |
CA2379385A1 (en) * | 1999-07-16 | 2001-01-25 | John C. Phelan | Thermoformable ophthalmic lens |
-
2001
- 2001-02-28 US US09/796,174 patent/US6679605B2/en not_active Expired - Lifetime
- 2001-03-16 DE DE60112570T patent/DE60112570T2/en not_active Expired - Lifetime
- 2001-03-16 EP EP01916703A patent/EP1289740B1/en not_active Expired - Lifetime
- 2001-03-16 WO PCT/US2001/008466 patent/WO2001089816A1/en active IP Right Grant
- 2001-03-16 AT AT01916703T patent/ATE301542T1/en not_active IP Right Cessation
- 2001-03-16 AU AU2001243692A patent/AU2001243692A1/en not_active Abandoned
- 2001-03-16 CA CA002407958A patent/CA2407958A1/en not_active Abandoned
- 2001-03-16 BR BR0111056-0A patent/BR0111056A/en not_active Application Discontinuation
- 2001-03-16 ES ES01916703T patent/ES2247081T3/en not_active Expired - Lifetime
- 2001-03-16 MX MXPA02011564A patent/MXPA02011564A/en active IP Right Grant
- 2001-03-16 JP JP2001586036A patent/JP2003534070A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP1289740B1 (en) | 2005-08-10 |
AU2001243692A1 (en) | 2001-12-03 |
US6679605B2 (en) | 2004-01-20 |
BR0111056A (en) | 2003-04-15 |
ES2247081T3 (en) | 2006-03-01 |
EP1289740A1 (en) | 2003-03-12 |
WO2001089816A1 (en) | 2001-11-29 |
JP2003534070A (en) | 2003-11-18 |
DE60112570D1 (en) | 2005-09-15 |
ATE301542T1 (en) | 2005-08-15 |
US20020161437A1 (en) | 2002-10-31 |
MXPA02011564A (en) | 2004-09-06 |
DE60112570T2 (en) | 2006-06-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1289740B1 (en) | Crystalline polymeric compositions for ophthalmic devices | |
EP1206293B8 (en) | Homopolymers containing crosslinkers and ocular implants made therefrom | |
US4834750A (en) | Deformable-elastic intraocular lens | |
AU2007230747B2 (en) | Novel hybrid intraocular lens materials for small incision surgery | |
JP5096793B2 (en) | Polymer composition and ophthalmic lens body | |
AU2005336100B2 (en) | Biocompatible polymeric compositions for use in making anterior chamber intraocular lenses | |
JP2002502666A (en) | Stretched crystalline elastomer medical implant and method of implantation | |
EP1816985B1 (en) | Biocompatible polymeric compositions for use in making posterior chamber intraocular lenses | |
AU661306B2 (en) | Deformable-elastic intraocular lens | |
US20140277438A1 (en) | Crystalline polymeric compositions for ophthalmic devices | |
WO2020226588A1 (en) | A new advanced formulation for hydrophobic intraocular lenses and their production method | |
EP1166155A1 (en) | Polymeric material compositions and intraocular lenses made from same | |
CZ20002905A3 (en) | Medicinal implant and intraocular implant | |
MXPA00007905A (en) | Medical implants of stretch-crystallizable elastomers and methods of implantation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Discontinued |